GLP-1 RAs and SGLT2is exhibit different mechanisms that affect glucose metabolism; consequently, GLP-1 RAs are typically added to current antiglycemic treatments if there is ongoing hyperglycemia despite treatment and after taking patient factors into account [18, 84]. This evidence concerns the gene GLP1R and Hyperglycemia.